Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Watson Pharmaceuticals Inc's Watson Laboratories, Inc Receives FDA Approval


Friday, 12 Oct 2012 04:03pm EDT 

Watson Pharmaceuticals Inc announced that its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Irbesartan Tablets USP, 75 mg, 150 mg and 300 mg, the generic equivalent to Sanofi's Avapro. Watson intends to begin shipping the product immediately. Avapro is indicated for the treatment of hypertension when used alone or in combination with other antihypertensive agents. It is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. 

Company Quote

227.31
1.06 +0.47%
22 Aug 2014